Eyeworld

39 EW FEATURE of people would seriously consider it, and in the U.S., almost 80% of surgeons would consider something like that." Dr. Barry likewise thinks it is inevitable that intracameral antibi- otics will prevail in the U.S. "I think that surgeons want to use them, and the number using them is rising," he said. "But if [surgeons are] using them they need the protection of an approved product, particularly when an approved product [Aprokam] actually exists." EW References 1. Barry P, Seal DV, Gettinby G, et al. ESCRS Endophthalmitis Study Group. ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery: preliminary report of principal results from a European multicenter study. J Cataract Refract Surg. 2006;32: 407–10. 2. Shorstein NH, Winthrop KL, Herrinton LJ. Decreased postoperative endophthalmitis rate after institution of intracameral antibiotics in a Northern California eye department. J Cataract Refract Surg. 2013; 39:8–14. 3. Friling E, Lundström M, Stenevi U, et al. Six-year incidence of endophthalmitis after cataract surgery: Swedish national study. J Cataract Refract Surg. 2013; 39:15–21. 4. Wejde G, Montan P, Lundström M, et. Al. Endophthalmitis following cataract surgery in Sweden: national prospective survey 1999–2001. Acta Ophthalmologica Scandinavia. 2005; 83:7–10. 5. Barry P. Adoption of intracameral antibiotic prophylaxis of endophthalmitis following cataract surgery: update on the ESCRS Endophthalmitis Study. J Cataract Refract Surg. 2014; 40:138–42. 6. Allen HF, Mangiaracine AB. Bacterial endophthalmitis after cataract extraction. A study of 22 infections in 20,000 operations. Archives of Ophthalmology. 1964; 72:454–6. 7. Allen HF, Mangiaracine AB. Bacterial endophthalmitis after cataract extraction II. Incidence in 36,000 consecutive operations with special reference to preoperative topical antibiotics. Archives of Ophthalmology. 1974;91:3–7. Editors' note: Dr. Barry has financial interests with Spectrum Thea (Newcastle, U.K.). Drs. Mah and Talley Rostov have no financial interests related to their comments. Contact information Barry: peterbarryfrcs@eircom.net Mah: mah.francis@scrippshealth.org Talley Rostov: atalleyrostov@nweyes.com intracameral cefuroxime reduces the rate of endophthalmitis, Dr. Mah said. While he concedes that the support in the literature is much stronger for intracameral antibiotics, he thinks that before changing anti- biotic protocols, practitioners should consider their own endophthalmitis rates. The literature pegs the average at about 1 in 1,000, with some pa- pers putting the rate at 1 in 5,000. "I think if you're at that 1 in 1,000 ratio or even better, that's pretty good, so I don't know that you necessarily have to change what you're doing," he said. Although Dr. Mah himself is a topical antibiotic user and noted that in 15 years, he has never had a case of endophthalmitis, he is currently transitioning to intraca- meral antibiotics. Having said that, Dr. Mah noted each surgeon must evaluate the data and their practice pattern. "I don't see how I could push someone else to look at something that might potentially complicate surgery," he said. There might, for example, be concerns about TASS or anaphylaxis with intracameral medications in the U.S. where such medications must be compounded because there is no FDA-approved option. Meanwhile, Dr. Talley Rostov embraces the intracameral approach, which she started using years ago af- ter experiencing just 1 endophthal- mitis case. Initially she started using antibiotics in the bottle, but then moved on from this. "I switched over from vancomycin in the bottle to the intracameral when the Shorstein article came out," Dr. Talley Rostov said. "I routinely employ the use of intracameral antibiotics at the end of the case, then I still use topical antibiotics for a week following." She hopes that others in the U.S. follow suit based on the evi- dence. Going forward, Dr. Mah thinks that practice patterns in the U.S. will ultimately change because the literature supports intracameral antibiotics. "Most people are looking for a single use, fool-proof method with the optimal medication—the kind of FDA-approved method," he said. "If that was available, the data are showing that in Europe 90% once an antibiotic is applied. "The only problem is that no one has ever prospectively shown that topical antibiotics actually correlate with a reduction in endophthalmitis," Dr. Mah said. "I think that a lot of the evidence in the literature right now for topical is retrospective and surrogate evidence." To date, the only prospective trial that has been done using topical antibiotics was the ESCRS study, which compared this with the intracameral approach, Dr. Mah said. "Their study showed that top- ical levofloxacin 0.5% did nothing in terms of reducing the rate of endophthalmitis," Dr. Mah said. He added that this older generation topical fluoroquinolone might not have been the best choice. Dr. Mah also raised the concern that the study might not have been large enough to find the difference. "They had more than 16,000 patients, but if you have a rate of endophthal- mitis of approximately 1 in 1,000, you need closer to 50,000 to 70,000 patients," he said. "So there isn't any prospective evidence that topical antibiotics do in fact reduce endophthalmitis." However, this study did show that intracameral antibiotics reduce the rate of endophthalmitis, he said. All in all, there have been 4 prospective studies showing that Topical literature In addition to the intracameral approach, the literature holds some support for topical antibiotics, said Francis Mah, MD, director of cornea and external disease, and co-director of refractive surgery, Scripps Clinic, La Jolla, Calif. There are retrospec- tive studies showing efficacy of the topical antibiotic approach for cataract procedures that date back to 1964 with a study that involved more than 20,000 cases, 6 he said. "Henry Allen showed that not using preoperative antibiotics was a significant risk factor for postopera- tive infections," Dr. Mah said. "The same group in 1974 showed that switching an antibiotic can further reduce the rate of endophthalmi- tis retrospectively." 7 More recently there have been several papers on the fluoroquinolones retrospectively showing that they have reduced the rate of endophthalmitis more and that by switching to a different flu- oroquinolone you could potentially reduce the rate further, he said. In addition to the retrospec- tive approach, many studies have considered how the patient's own flora fares against antibiotics, Dr. Mah noted. Evidence with the use of povidone-iodine has shown that this was the origin of endophthalmitis in about 80% of cases. Some studies consider whether colonies survive " I think that surgeons want to use [intracameral antibiotics], and the number using them is rising. But if [surgeons are] using them they need the protection of an approved product, particularly when an approved product [Aprokam] actually exists. " –Peter Barry, MD January 2015 Intracameral antibiotics

• Cover